Efnisyfirlit

• Instructions for online access
• Cover image
• Title Page
• Table of Contents
• Copyright
• How to Use These Cards
• Preface
• Acknowledgements
• Abbreviations
• Section I Cholinergic pharmacology
  • 1.01 Muscarinics – Eye
  • 1.02 Antimuscarinics – Eye
  • 1.03 Antimuscarinics – Gastrointestinal
  • 1.04 Antimuscarinics – Bladder
  • 1.05 Neuromuscular Blocker
  • 1.06 Neuromuscular Blocker
  • 1.07 Peripheral Anticholinesterases
  • 1.08 Nicotinic Partial Agonists
• Section II Noradrenergic pharmacology
  • 2.01 β2-Receptor Agonist
  • 2.02 β1-Receptor Antagonist
  • 2.03 α- and β-Receptor Agonists
  • 2.04 α1-Receptor Antagonist
  • 2.05 β1-Receptor Agonist
  • 2.06 α1-Receptor Agonist
  • 2.07 Drugs That Release Noradrenaline
  • 2.08 Selective β3-Adrenoceptor Agonist
  • 2.09 α2-Agonist Prodrug
  • 2.10 DOPA Decarboxylase Inhibitor
• Section III Inflammation and anti-inflammatory drugs
  • 3.01 NSAIDs
  • 3.02 NSAIDs
  • 3.03 NSAIDs
  • 3.04 COX-2 Inhibitors
  • 3.05 DMARDs
  • 3.06 DMARDs
  • 3.07 DMARDs
  • 3.08 Uricosuric Agents
  • 3.09 Antigout: Colchicine
  • Notes
• Section IV Drugs affecting the immune response
  • 4.01 Calcineurin Inhibitors
  • 4.02 Antiproliferative Immunosuppressant
  • 4.03 Antiproliferative Immunosuppressant
  • 4.04 Antiproliferative Antibiotic
  • 4.05 Glucocorticoids
  • 4.06 TNF Inhibitors
  • 4.07 Antibodies Against CD20
  • 4.08 Monoclonal Antibodies (non-CD20)
  • 4.09 Interleukin Inhibitors
  • 4.10 JAK
  • 4.11 Non-Sedating Antihistamines
  • 4.12 Sedating Antihistamine
  • 4.13 Drugs Affecting the Immune Response
• Section V Antidysrhythmic drugs
  • 5.01 Class Ia Antidysrhythmic
  • 5.02 Class Ic Antidysrhythmic
  • 5.03 Class II Antidysrhythmic
  • 5.04 Class III Antidysrhythmic
  • 5.05 Class IV Antidysrhythmic
  • 5.06 Adenosine Receptor Agonists
  • 5.07 Cardiac Glycoside
• Section IV The vascular system
  • 6.01 ACE Inhibitors
  • 6.02 Angiotensin Antagonists
  • 6.03 Calcium Channel Blockers
  • 6.04 Potassium Channel Activator
  • 6.05 Hydralazine
  • 6.06 Endothelin Antagonist
• Section VII The heart
  • 7.01 Nitrates
  • 7.02 Ivabradine
  • 7.03 Ranolazine
• Section VIII Drugs for eye and skin conditions
  • 8.01 Glaucoma Eyedrops
  • Notes
  • 8.02 VEGF Inhibitors
  • Notes
  • 8.03 Retinoids
  • 8.04 Treatment of Psoriasis
  • Notes
  • 8.05 Skin Parasites
  • Notes
• Section IX Atherosclerosis and lipoprotein metabolism
  • 9.01 HMG-CoA Reductase Inhibitors
  • 9.02 Fibrates
  • 9.03 PCSK9 Inhibitors
  • 9.04 Cholesterol-Absorption Inhibitors
  • 9.05 Cholesterol-Absorption Inhibitors
• Section X Haemostasis and thrombosis
  • 10.01 Irreversible COX-1 Inhibitor
  • 10.02 Adenosine (P2Y12) Antagonists
  • 10.03 GPIIb/IIIa Receptor Antagonists
  • 10.04 Other Antiplatelets Drugs
  • 10.05 Plasminogen Activators
  • 10.06 Plasminogen Inhibitor
  • 10.07 Anticoagulants
  • 10.08 Anticoagulants
  • 10.09 Anticoagulants
  • 10.10 Direct Oral Anticoagulants
• Section XI Haemopoietic system and treatment of anaemia
  • 11.01 Haematinic Agents
  • 11.02 Haematinic Agents
  • 11.03 Haematinic Agents
  • 11.04 Haemopoietic Growth Factors
  • 11.05 Haemopoietic Growth Factors
• Section XII Respiratory system
  • 12.01 β2-Receptor Agonists
  • 12.02 Xanthines
  • 12.03 Leukotriene Antagonists
  • 12.04 Inhaled Muscarinic Antagonists
  • 12.05 Inhaled Glucocorticoids
  • 12.06 Inhibitor of Mast Cells
  • 12.07 Inhibition of Interleukin-5
  • 12.08 Anti-Fibrotic Agents
  • Notes
• Section XIII Kidney
  • 13.01 Loop Diuretics
  • 13.02 Thiazide Diuretics
  • 13.03 Potassium-Sparing Diuretics
  • 13.04 Osmotic Diuretic
• Section XIV Gastrointestinal tract drugs
  • 14.01 H2 Antagonist
  • 14.02 Proton Pump Inhibitors
  • 14.03 Mucosal Protectants
  • 14.04 Antacids
  • 14.05 Prostaglandin E Agonist
  • 14.06 5-HT3 Antagonists – Antiemetics
  • 14.07 Other Antiemetics
  • 14.08 Osmotic Laxatives
  • 14.09 Bulk Laxatives
  • 14.10 Stimulant Laxatives
  • 14.11 Faecal Softeners
  • 14.12 Other Drugs for Constipation
  • 14.13 Antidiarrhoeal Agent
  • 14.14 Other Drugs That Reduce GI Motility
• Section XV The control of blood glucose and drug treatment of diabetes mellitus
  • 15.01 Insulin
  • 15.02 Sulfonylureas
  • 15.03 Biguanides
  • 15.04 Meglitinides
  • 15.05 Glucagon-Like Peptide-1 Agonists
  • 15.06 Dipeptidyl Peptidase Inhibitors
  • 15.07 SGLT-2 Inhibitors
  • 15.08 α-Glucosidase Inhibitors
  • 15.09 Glucagon
• Section XVI The pituitary and the adrenal cortex
  • 16.01 Hypothalamic Hormones
  • 16.02 Hypothalamic Hormones
  • 16.03 Anterior Pituitary Hormones
  • 16.04 Posterior Pituitary Hormones
  • 16.05 Mineralocorticoid
• Section XVII The thyroid
  • 17.01 Thyroid Hormone Suppression
  • 17.02 Thyroid Hormone Replacement
• Section XVIII Bone metabolism
  • 18.01 Antiresorptive Drugs
  • 18.02 Antiresorptive Drugs
  • 18.03 Antiresorptive Drugs
  • 18.04 Antiresorptive Drugs
  • 18.05 Anabolic Agents
  • 18.06 Vitamin D Preparations
• Section XIX Reproductive system
  • 19.01 Oestrogens and Anti-Oestrogens
  • 19.02 Progestogens and Anti-Progestogens
  • 19.03 Combined Oral Contraceptive Pill
  • 19.04 Gonadotrophins
  • 19.05 Uterine Stimulants
  • 19.06 Uterine Stimulants
  • 19.07 Uterine Stimulants
  • 19.08 Oxytocin Antagonist
  • 19.09 Male Sex Hormone
  • 19.10 Anti-Androgens
  • 19.11 Phosphodiesterase Type V Inhibitors
• Section XX Neurodegenerative disorders
  • 20.01 Drugs Used in Parkinson's Disease
  • 20.02 Drugs Used in Parkinson's Disease
  • 20.03 Drugs Used in Parkinson's Disease
  • 20.04 Drugs Used in Parkinson's Disease
  • 20.05 Drugs Used in Parkinson's Disease
  • 20.06 Drugs Used in Parkinson's Disease
  • 20.07 Drugs Used in Alzheimer's Disease
  • 20.08 Drugs Used in Alzheimer's Disease
  • 20.09 Drugs Used in Multiple Sclerosis
  • Notes
• Section XXI General anaesthetics
  • 21.01 Inhalational Agents
  • 21.02 Inhalational Agents
  • 21.03 Intravenous Anaesthesia
• Section XXII Anxiolytics and hypnotic drugs
  • 22.01 Benzodiazepines
  • 22.02 Z-drugs
  • 22.03 Partial Serotonin Agonist
  • 22.04 Other Insomnia Drugs
  • Notes
• Section XXIII Antipsychotic drugs
  • 23.01 First-Generation Antipsychotics
  • 23.02 First-Generation Antipsychotics
  • 23.03 First-Generation Antipsychotics
  • 23.04 Second-Generation Antipsychotics
  • 23.05 Second-Generation Antipsychotics
  • 23.06 Second-Generation Antipsychotics
  • 23.07 Second-Generation Antipsychotics
  • 23.08 Second-Generation Antipsychotics
• Section XXIV Antidepressant drugs
  • 24.01 Tricyclics
  • 24.02 SSRIs
  • 24.03 SNRIs
  • 24.04 Noradrenaline Reuptake Inhibitor
  • 24.05 Monoamine Oxidase Inhibitors
  • 24.06 α-Adrenoceptor & 5-HT Receptor Antagonist
  • 24.07 Dopamine Reuptake Inhibitor
  • 24.08 Drugs for Bipolar Disorder
  • 24.09 Drugs for Bipolar Disorder
  • Notes
• Section XXV Antiepileptic drugs
  • 25.01 Sodium Channel Inhibitors
  • 25.02 T-Type Calcium Channel Blockers
  • 25.03 Broad-Spectrum Antiepileptic
  • 25.04 Benzodiazepines
  • 25.05 Barbiturates
  • 25.06 Broad-Spectrum Antiepileptic
  • 25.07 Broad-Spectrum Antiepileptic
  • 25.08 AMPA Receptor Blockers
  • 25.09 Broad-Spectrum Antiepileptic
  • 25.10 Other Anticonvulsants
• Section XXVI Analgesic drugs
  • 26.01 Opioid Drugs
  • 26.02 Opioid Drugs
  • 26.03 Opioid Drugs
  • 26.04 Opioid Drugs
  • 26.05 Drugs Used for Neuropathic Pain
  • 26.06 Drugs Used for Neuropathic Pain
  • 26.07 Drugs Used for Neuropathic Pain
  • 26.08 Other Analgesic Drugs
  • Notes
• Section XXVII Psychoactive drugs
  • 27.01 Psychomotor Stimulants
  • 27.02 Psychomotor Stimulants
  • 27.03 Psychomotor Stimulants
  • 27.04 CNS Depressants
  • 27.05 Other Psychoactive Drugs
  • Notes
  • 27.06 Major Psychedelic Drugs
• Section XXVIII Local anaesthetics
  • 28.01 Rapid-Onset LAs
  • 28.02 Slow- and Medium-Onset LAs
  • 28.03 Topical LA
• Section XXIX Antibacterial drugs
  • 29.01 Beta-Lactam Antibiotics
  • 29.02 Beta-Lactam Antibiotics
  • 29.03 Beta-Lactam Antibiotics
  • 29.04 Blockers of Peptidoglycan Synthesis
  • 29.05 Bacterial Protein Synthesis Blockers
  • 29.06 Bacterial Protein Synthesis Blockers
  • 29.07 Bacterial Protein Synthesis Blockers
  • 29.08 Bacterial Protein Synthesis Blockers
  • 29.09 Bacterial Protein Synthesis Blockers
  • 29.10 Antibiotics Affecting Topoisomerase
  • 29.11 Blockers of Folate Synthesis/Action
  • 29.12 Other Antibacterial Drugs
  • Notes
  • 29.13 Antimycobacterials for Tuberculosis
  • Notes
  • 29.14 Antimycobacterials for Leprosy
  • Notes
• Section XXX Antiviral drugs
  • 30.01 Reverse Transcriptase Inhibitors
  • 30.02 Reverse Transcriptase Inhibitors
  • 30.03 Protease Inhibitors
  • 30.04 DNA Polymerase Inhibitors
  • 30.05 Neuraminidase Inhibitors
  • 30.06 Biopharmaceutical Antivirals
  • Notes
  • 30.07 Drugs Used in HIV
  • Notes
  • 30.08 Drugs Used in Hepatitis
  • Notes
• Section XXXI Antiprotozoal drugs
  • 31.01 Blood Schizonticides – Malaria
  • 31.02 Tissue Schizonticide – Malaria
  • 31.03 Folate Inhibitors – Malaria
  • 31.04 Artemisinin Derivatives – Malaria
  • 31.05 Treatment of Amoebiasis
  • 31.06 Other Antiprotozoal Drugs
• Section XXXII Antifungal drugs
  • 32.01 Antifungal Antibiotics
  • 32.02 Synthetic Antifungal Drugs – Azoles
  • 32.03 Other Antifungal Drugs
• Section XXXIII Mebendazole
  • 33.01 Anthelminthic Drugs
  • 33.02 Anthelminthic Drugs
  • 33.03 Anthelminthic Drugs
  • 33.04 Anthelminthic Drugs
  • 33.05 Anthelminthic Drugs
  • 33.06 Anthelminthic Drugs
  • 33.07 Anthelminthic Drugs
• Section XXXIV Anticancer drugs
  • 34.01 Alkylating Agents and Similar Drugs
  • 34.02 Antimetabolites
  • 34.03 Cytotoxic Antibiotics
  • 34.04 Plant Derivatives
  • 34.05 Hormones
  • 34.06 Protein Kinase Inhibitors
  • 34.07 Monoclonal Antibodies
  • 34.08 Anticancer Drugs
• Section XXXV General principles
  • 35.01 Agonists and Antagonists
  • 35.02 Affinity
  • 35.03 Efficacy
  • 35.04 Competitive Antagonism
• Section XXXVI Genetic variation and personalized medicine
  • 36.01 Drug Efficacy
  • 36.02 Drug Safety
  • 36.03 Pharmacokinetics
• Section XXXVII Absorption and distribution of drugs
  • 37.01 Lipid Solubility and Ionization
  • 37.02 Routes of Drug Administration
  • 37.03 Bioavailability
  • 37.04 Measurement of Bioavailability
  • 37.05 Non-Target Binding of Drugs
  • 37.06 Volume of Distribution, Vd
• Section XXXVIII Drug metabolism and excretion
  • 38.01 Phase I and Phase II Metabolism
  • 38.02 Cytochrome P450 System
  • 38.03 P450 Induction and Inhibition
  • 38.04 Renal Excretion of Drugs
  • 38.05 Other Routes of Excretion
• Section XXXIX Pharmacokinetics
  • 39.01 First-Order Elimination
  • 39.02 Zero-Order Elimination
  • 39.03 Plasma Half-Life
  • 39.04 Clearance
• Drug Index

UM RAFBÆKUR Á HEIMKAUP.IS

Bókahillan þín er þitt svæði og þar eru bækurnar þínar geymdar. Þú kemst í bókahilluna þína hvar og hvenær sem er í tölvu eða snjalltæki. Einfalt og þægilegt!

Rafbók til eignar
Rafbók til eignar þarf að hlaða niður á þau tæki sem þú vilt nota innan eins árs frá því bókin er keypt.

Þú kemst í bækurnar hvar sem er
Þú getur nálgast allar raf(skóla)bækurnar þínar á einu augabragði, hvar og hvenær sem er í bókahillunni þinni. Engin taska, enginn kyndill og ekkert vesen (hvað þá yfirvigt).

Auðvelt að fletta og leita
Þú getur flakkað milli síðna og kafla eins og þér hentar best og farið beint í ákveðna kafla úr efnisyfirlitinu. Í leitinni finnur þú orð, kafla eða síður í einum smelli.

Glósur og yfirstrikanir
Þú getur auðkennt textabrot með mismunandi litum og skrifað glósur að vild í rafbókina. Þú getur jafnvel séð glósur og yfirstrikanir hjá bekkjarsystkinum og kennara ef þeir leyfa það. Allt á einum stað.

Hvað viltu sjá? / Þú ræður hvernig síðan lítur út
Þú lagar síðuna að þínum þörfum. Stækkaðu eða minnkaðu myndir og texta með multi-level zoom til að sjá síðuna eins og þér hentar best í þínu námi.



Fleiri góðir kostir
- Þú getur prentað síður úr bókinni (innan þeirra marka sem útgefandinn setur)
- Möguleiki á tengingu við annað stafrænt og gagnvirkt efni, svo sem myndbönd eða spurningar úr efninu
- Auðvelt að afrita og líma efni/texta fyrir t.d. heimaverkefni eða ritgerðir
- Styður tækni sem hjálpar nemendum með sjón- eða heyrnarskerðingu